Bernd Muhlbauer
Overview
Explore the profile of Bernd Muhlbauer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
589
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Veselinovic T, Scharpenberg M, Heinze M, Cordes J, Muhlbauer B, Juckel G, et al.
J Clin Psychopharmacol
. 2019 Nov;
39(6):550-560.
PMID: 31688449
Background: Impaired subjective well-being in schizophrenia patients treated with antipsychotics has often been linked inter alia to the antidopaminergic effects of medication. Thus, it is important to capture the association...
3.
Veselinovic T, Scharpenberg M, Heinze M, Cordes J, Muhlbauer B, Juckel G, et al.
Eur Neuropsychopharmacol
. 2019 Apr;
29(6):720-739.
PMID: 30981585
Cognitive impairment represents a core feature of schizophrenia. Uncertainty about demonstrable benefits of available antipsychotics on cognition remains an important clinical question relevant to patients' quality of life. The aim...
4.
Muhlbauer B
Z Evid Fortbild Qual Gesundhwes
. 2016 Jun;
112 Suppl 1:S34-7.
PMID: 27320027
In 2014, a pilot project of the European licensing authority EMA was launched to explore new ways to license medicinal products. The intention of this project is to open up...
5.
Wille H, Muhlbauer B
Z Evid Fortbild Qual Gesundhwes
. 2016 Jun;
110-111:107-8.
PMID: 27295731
No abstract available.
6.
Grunder G, Heinze M, Cordes J, Muhlbauer B, Juckel G, Schulz C, et al.
Lancet Psychiatry
. 2016 Jun;
3(8):717-729.
PMID: 27265548
Background: Whether or not second-generation antipsychotics (SGAs) represent an advantage over first-generation antipsychotics (FGAs) in the treatment of schizophrenia is not certain. Effectiveness studies published in the past 10 years...
7.
Schulz C, Timm J, Cordes J, Grunder G, Muhlbauer B, Ruther E, et al.
Clin Trials
. 2016 Mar;
13(3):262-3.
PMID: 27016731
No abstract available.
8.
Schulz C, Timm J, Cordes J, Grunder G, Muhlbauer B, Ruther E, et al.
Clin Trials
. 2016 Mar;
13(3):251-9.
PMID: 27016729
Background: The 'gold standard' for clinical studies is a randomised controlled trial usually comparing specific treatments. If the scientific study expands to strategy comparison with each strategy including various treatments,...
9.
Schott G, Lieb K, Konig J, Muhlbauer B, Niebling W, Pachl H, et al.
Dtsch Arztebl Int
. 2015 Jul;
112(26):445-51.
PMID: 26205748
Background: Authors' conflicts of interest may affect the content of medical guidelines. In April 2010, the Association of Scientific Medical Societies in Germany (AWMF) issued recommendations on how such conflicts...
10.
Stammschulte T, Ludwig W, Muhlbauer B, Bronder E, Gundert-Remy U
Eur J Clin Pharmacol
. 2015 Jul;
71(9):1129-38.
PMID: 26169297
Purpose: In 1986, the risk of agranulocytosis prompted German authorities to restrict the indications for metamizole use. After an initial decline, prescriptions increased from <20 million defined daily doses in...